Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants

Trial Profile

A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs RO-7017773 (Primary) ; Benzodiazepines
  • Indications Autistic disorder
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 08 Oct 2018 Status changed from recruiting to completed.
    • 05 Oct 2018 Planned End Date changed from 5 Oct 2018 to 30 Nov 2018.
    • 05 Oct 2018 Planned primary completion date changed from 8 Sep 2018 to 30 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top